{"id":"W4411643018","doi":"10.1016/j.esmoop.2025.105199","title":"69O Novel regimens for persistent/recurrent rare epithelial ovarian carcinomas (EOCs) selected according to biomarker status: ENGOT-GYN2/GOG-3051/BOUQUET phase II study results","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre; Princess Margaret Cancer Centre; University of Toronto","funders":"Daiichi Sankyo Europe; Defence and Security Accelerator; Takeda Oncology; Genentech; PharmaMar; European Society for Medical Oncology; Eisai; AbbVie; European Commission; Seagen; Merck; Mersana Therapeutics; Amgen; Deciphera Pharmaceuticals; AstraZeneca; Novocure; Regeneron Pharmaceuticals; Sociedad Española de Oncología Médica; Eisai Canada; BeiGene; Clovis Oncology; Pfizer; Incyte; F. Hoffmann-La Roche; Myriad Genetics; Bristol-Myers Squibb; American Society of Clinical Oncology; Vifor Pharma","keywords":"Oncology; Ovarian carcinomas; Biomarker; Ovarian cancer; Internal medicine; Medicine; Phases of clinical research; Epithelial ovarian cancer; Ovarian carcinoma; Biology; Cancer; Toxicity","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006838613,0.0004967403,0.0009021743,0.0003816178,0.0006028389,0.0002410154,0.0004918771,0.0001433642,0.0001453068],"category_scores_gemma":[0.0005414166,0.0004312423,0.0002757769,0.001043075,0.00004264319,0.0002106433,0.0005027198,0.0002384002,0.00002829557],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008573023,"about_ca_system_score_gemma":0.0009732713,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005188858,"about_ca_topic_score_gemma":0.001418381,"domain_scores_codex":[0.9966494,0.0001242625,0.0007580927,0.001242544,0.0003808464,0.0008448771],"domain_scores_gemma":[0.9975654,0.0002660757,0.0002093658,0.001007914,0.0004898838,0.0004613884],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.1097075,0.08227001,0.1170557,0.0008365827,0.02012779,0.0008515329,0.0437731,0.00008677586,0.01159309,0.003862493,0.3043375,0.3054979],"study_design_scores_gemma":[0.1900028,0.02838887,0.2437536,0.001643909,0.004262056,0.00003863282,0.01421545,0.0006768755,0.008704289,0.00007192466,0.5068661,0.001375439],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9496871,0.0004531968,0.0006353807,0.01710719,0.001847428,0.01725433,0.003943006,0.0001805072,0.008891815],"genre_scores_gemma":[0.9886209,0.00003629269,0.003116735,0.0008547226,0.0002442824,0.001945841,0.0009101224,0.00006783294,0.004203231],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3041225,"threshold_uncertainty_score":0.9998139,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06490799290462351,"score_gpt":0.3777180111971781,"score_spread":0.3128100182925546,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}